$PTX,
Analyst Price Target Update on Pernix Therapeutics Holdings (NASDAQ
TX)
Andy Clarke June 14, 2016 No Comments on Analyst Price Target Update on Pernix Therapeutics Holdings (NASDAQTX)
Pernix Therapeutics Holdings (NASDAQTX) should head towards $6.5 per share according to 2 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $3 per share. The higher price estimate target is at $10 according to the Analysts.
Many analysts have stated their opinion on the company shares. Oppenheimer downgrades its rating on Pernix Therapeutics Holdings (NASDAQTX). Analysts at the Oppenheimer have a current rating of Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on March 17, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Siegel Barry J, officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc., had purchased 5,000 shares on August 19, 2015. The total value of the transaction was $22,450. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Pernix Therapeutics Holdings (NASDAQTX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.0402 points or 6.93% at $0.5398 with 4,726,420 shares getting traded. Post opening the session at $0.59, the shares hit an intraday low of $0.528 and an intraday high of $0.59 and the price was in this range throughout the day. The company has a market cap of $33 million and the number of outstanding shares have been calculated to be 61,127,965 shares. The 52-week high of Pernix Therapeutics Holdings (NASDAQTX) is $6.44 and the 52-week low is $0.3901.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).
Analyst Price Target Update on Pernix Therapeutics Holdings (NASDAQ
TX) Andy Clarke June 14, 2016 No Comments on Analyst Price Target Update on Pernix Therapeutics Holdings (NASDAQ
TX) Pernix Therapeutics Holdings (NASDAQ
TX) should head towards $6.5 per share according to 2 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $3 per share. The higher price estimate target is at $10 according to the Analysts. Many analysts have stated their opinion on the company shares. Oppenheimer downgrades its rating on Pernix Therapeutics Holdings (NASDAQ
TX). Analysts at the Oppenheimer have a current rating of Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on March 17, 2016. For the current week, the company shares have a recommendation consensus of Buy. On the companys insider trading activities, Siegel Barry J, officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc., had purchased 5,000 shares on August 19, 2015. The total value of the transaction was $22,450. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Pernix Therapeutics Holdings (NASDAQ
TX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.0402 points or 6.93% at $0.5398 with 4,726,420 shares getting traded. Post opening the session at $0.59, the shares hit an intraday low of $0.528 and an intraday high of $0.59 and the price was in this range throughout the day. The company has a market cap of $33 million and the number of outstanding shares have been calculated to be 61,127,965 shares. The 52-week high of Pernix Therapeutics Holdings (NASDAQTX) is $6.44 and the 52-week low is $0.3901. Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
